Last updated: September 1, 2026
Azelastine hydrochloride/fluticasone propionate is a combination nasal suspension marketed in the United States as Dymista. The product combines an intranasal antihistamine with a corticosteroid for seasonal allergic rhinitis. Its commercial opportunity is concentrated in generic and differentiated nasal-spray products that improve suspension stability, spray performance, tolerability, preservative exposure, device usability, and manufacturing efficiency.
The reference product uses a multidose, pump-delivered aqueous suspension. The principal excipient decisions concern particle suspension, viscosity, microbial control, redispersibility, nasal residence time, and compatibility with the metered-dose device. Because both active ingredients are established small molecules, the most defensible product differentiation is likely to come from formulation and device performance rather than new pharmacology.
What is azelastine hydrochloride and fluticasone propionate nasal spray?
Azelastine hydrochloride/fluticasone propionate nasal spray is a fixed-dose combination containing 137 micrograms of azelastine hydrochloride and 50 micrograms of fluticasone propionate per spray. The labeled dose for adults and adolescents aged 12 years and older is one spray in each nostril twice daily. The same dose is used in pediatric patients aged 6 to 11 years under the U.S. prescribing information.[1]
Azelastine hydrochloride is an H1-receptor antagonist. Fluticasone propionate is a glucocorticoid with anti-inflammatory activity. The combination targets congestion, sneezing, itching, and rhinorrhea associated with seasonal allergic rhinitis.
Dymista was approved by the U.S. Food and Drug Administration in 2012 under NDA 202236.[1] The product is prescription-only in the United States. It is not a biologic and does not create a biosimilar pathway.
What excipients are used in Dymista nasal spray?
The reference product uses excipients selected for a stable aqueous suspension and controlled nasal delivery.
| Excipient |
Primary formulation function |
| Microcrystalline cellulose |
Suspending agent and rheology modifier |
| Carboxymethylcellulose sodium |
Viscosity control and suspension stabilization |
| Dextrose |
Tonicity and formulation support |
| Benzalkonium chloride |
Preservative |
| Polysorbate 80 |
Wetting and dispersion aid |
| Disodium edetate |
Chelating agent and preservative-support excipient |
| Phenylethyl alcohol |
Preservative and formulation-support excipient |
| Purified water |
Continuous aqueous phase |
The product is a suspension rather than a simple solution because fluticasone propionate has very low aqueous solubility. The excipient system must keep the drug particles uniformly dispersed during storage and use while allowing the pump to deliver a reproducible dose after shaking.
Microcrystalline cellulose and carboxymethylcellulose sodium are central to the product’s physical stability. They increase structured viscosity at rest, which helps limit sedimentation. Under pump actuation and shaking, the formulation must remain sufficiently mobile to pass through the metering system.
Polysorbate 80 supports wetting and dispersion of hydrophobic drug particles. Disodium edetate can bind trace metal ions that may promote degradation or reduce preservative performance. Benzalkonium chloride and phenylethyl alcohol provide antimicrobial protection in a multidose container.
The precise qualitative and quantitative composition should be evaluated against the current FDA-approved labeling and product quality documentation. Small changes in polymer grade, preservative concentration, particle size, or pump geometry can change delivered-dose uniformity and nasal deposition.[1,2]
How does the excipient system affect product performance?
The commercial and regulatory performance of this product depends on five linked attributes.
Suspension stability
The formulation must resist settling, caking, aggregation, and irreversible sedimentation. A suspension that settles rapidly can produce inconsistent doses, particularly if the patient does not shake the container adequately.
Excipient selection should be assessed through:
- Sedimentation rate
- Redispersibility after storage
- Particle-size distribution
- Flocculation behavior
- Viscosity under low and high shear
- Delivered-dose uniformity throughout container use
Carboxymethylcellulose grade is commercially important. Molecular weight, substitution level, hydration rate, and microbial quality can materially affect sprayability and suspension behavior.
Sprayability and pump compatibility
A nasal suspension must pass through a narrow actuator pathway without clogging. Excessive viscosity can impair priming, plume formation, and dose delivery. Insufficient viscosity can increase settling and dose variability.
The formulation and device should be developed together. Key performance indicators include:
- Priming and repriming behavior
- Actuation force
- Spray pattern
- Plume geometry
- Droplet-size distribution
- Dose weight
- Container-life performance
- Clogging after intermittent use
A generic product may match the reference formulation qualitatively yet fail to match its delivered spray characteristics. That creates both regulatory and commercial risk.
Nasal tolerability
Benzalkonium chloride is effective in multidose nasal products but can raise tolerability and patient-preference concerns, particularly with chronic or repeated exposure. Potential commercial strategies include lower-preservative formulations, alternative preservative systems, or preservative-free unit-dose presentations.
Any preservative change must be evaluated for antimicrobial effectiveness, nasal safety, container compatibility, and product stability. Removing benzalkonium chloride without replacing its microbiological control can create a major quality defect.
Chemical stability
Azelastine hydrochloride and fluticasone propionate have different physicochemical properties. The formulation must control pH, oxidation risk, hydrolysis, light exposure, and interaction with container-closure materials.
Disodium edetate, polysorbate 80, and the selected water quality can influence degradation pathways. Extractables and leachables from the bottle, pump, gasket, and actuator also require evaluation.
Patient usability
Dymista is administered twice daily and requires shaking before use. Improvements in cap design, priming instructions, dose counters, actuation force, or ergonomic handling can support differentiation without changing the active ingredients.
Patient-use studies should measure whether users:
- Shake the product adequately
- Prime the pump correctly
- Maintain the correct head position
- Complete both nostril administrations
- Recognize when the container is empty
- Clean the actuator properly
What formulations are protected by the azelastine/fluticasone product strategy?
The strongest technical protection is likely to arise from the combination of formulation composition, particle properties, suspension behavior, and delivery-device performance.
Potentially protectable features include:
- Specific ratios or concentration ranges of microcrystalline cellulose and carboxymethylcellulose sodium.
- Defined fluticasone particle-size distributions.
- Suspension systems that maintain delivered-dose uniformity after extended storage.
- Preservative-free or reduced-preservative compositions.
- Unit-dose nasal presentations.
- Pump systems that reduce clogging or improve plume characteristics.
- Formulations with improved nasal retention or reduced drip.
- Manufacturing processes that produce a reproducible suspension without excessive aggregation.
- Packaging systems that limit moisture, oxidation, or extractables.
- Method-of-use claims directed to seasonal allergic rhinitis treatment.
Composition claims are generally stronger when they are tied to measurable product attributes. A broad claim covering the two active ingredients with conventional excipients may face prior-art pressure. Claims tied to particle size, rheology, dose uniformity, or a defined device may offer more defensible differentiation.
When did azelastine/fluticasone regulatory exclusivity expire?
The principal FDA regulatory exclusivity period for the combination has expired. Dymista was approved in 2012, and the relevant three-year exclusivity period associated with new clinical investigations would not continue beyond the middle of the decade.[1,3]
The product is not protected by new chemical entity exclusivity for both active ingredients because azelastine and fluticasone were previously approved active substances. Any current market barrier therefore depends primarily on listed patents, formulation or device patents, regulatory requirements, manufacturing capability, and commercial execution.
What is the Orange Book status of Dymista?
Dymista is listed in the FDA Orange Book as a prescription drug product with an approved NDA. The Orange Book should be reviewed for the current patent and exclusivity entries associated with NDA 202236, including any updates, delistings, or expiration changes.[3]
For generic applicants, the relevant pathway is an abbreviated new drug application. A complete strategy requires comparison of:
- Listed patents
- Paragraph IV certification risk
- Labeling carve-out opportunities
- Nasal-spray performance requirements
- Formulation sameness or permissible differences
- Device and container-closure obligations
- Potential patent litigation
The Orange Book is the controlling source for current listed-patent status. Patent expiration dates should not be inferred solely from broad family records because terminal disclaimers, patent-term adjustment, reexamination, maintenance status, and listing decisions can change the practical analysis.
Which companies are challenging or competing with Dymista?
Competition comes from three groups:
| Competitive group |
Products or strategies |
Commercial effect |
| Generic manufacturers |
ANDA versions of azelastine hydrochloride/fluticasone propionate nasal spray |
Price erosion and formulary substitution |
| Single-agent nasal products |
Fluticasone propionate, fluticasone furoate, azelastine hydrochloride |
Lower-cost alternatives and treatment sequencing |
| Branded allergy products |
Other combination or antihistamine/corticosteroid products |
Differentiation through convenience, tolerability, or delivery |
Generic manufacturers with established nasal-spray manufacturing capabilities are better positioned than companies with only oral-solid-dose infrastructure. The technical burden is higher than for a conventional tablet because the applicant must demonstrate consistent performance of a suspension and pump system.
Competition may intensify if multiple ANDA products launch near the same time. In that scenario, price becomes the primary differentiator unless one manufacturer secures a meaningful device, preservative, or usability advantage.
What generic entry risks exist?
Generic entry risk is high after regulatory exclusivity expiration, but launch timing depends on patent certifications, litigation, and regulatory approval.
Paragraph IV challenges
An ANDA applicant can make a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval under the Hatch-Waxman framework.[4]
For azelastine/fluticasone, litigation risk is most relevant to patents covering:
- The fixed-dose combination
- Suspension composition
- Particle-size control
- Nasal delivery
- Manufacturing methods
- Method of treating allergic rhinitis
A generic applicant may also seek approval with a Section viii labeling carve-out if a method-of-use claim can be omitted without removing the core approved indication. The feasibility of that approach depends on the exact Orange Book claims and FDA labeling.
Generic launch scenarios
| Scenario |
Likely market effect |
| Single first generic launch |
Moderate price reduction and strong early share capture |
| Multiple simultaneous launches |
Rapid price erosion and limited differentiation |
| Authorized generic or licensed launch |
Greater brand control over channel pricing |
| Delayed launch after patent settlement |
Continued branded pricing until agreed entry date |
| Preservative-free differentiated generic |
Premium niche positioning rather than immediate commodity pricing |
What licensing deals and commercial partnerships matter?
The principal commercial relationship is the transfer and expansion of Dymista commercialization from Meda to Mylan and subsequently Viatris through corporate transactions. That history matters because the product’s commercial rights, manufacturing network, and regulatory files may be distributed across corporate entities and regional affiliates.
For new entrants, licensing opportunities may involve:
- Regional rights to an approved or near-approved nasal suspension
- Contract manufacturing of the pump and suspension
- Device technology for preservative-free delivery
- Alternate bottle and actuator systems
- Particle-engineering technology for fluticasone propionate
- Co-development of pediatric or unit-dose presentations
A licensing target is more valuable when it includes an FDA-ready manufacturing process, device qualification, stability data, and freedom-to-operate analysis. An active-ingredient license alone has limited strategic value because both active substances are widely available.
How strong is the patent estate for azelastine/fluticasone?
The patent estate is more likely to be technically meaningful than chemically exclusive. The active ingredients are old, and broad composition-of-matter protection is unavailable. Residual strength can come from formulation and device claims, but these claims face greater invalidity and design-around exposure than new-molecule patents.
Patent strength should be scored across four dimensions:
| Dimension |
Assessment |
| Active-ingredient protection |
Weak or expired because both ingredients are established |
| Fixed-combination protection |
Potentially relevant, subject to prior art and claim scope |
| Formulation protection |
Commercially important where claims include measurable performance |
| Device and manufacturing protection |
Potentially strong if the process is difficult to reproduce or design around |
Manufacturing know-how may provide more practical protection than a narrow formulation patent. Critical know-how can include polymer hydration order, mixing energy, active-ingredient milling, bulk hold times, filling conditions, and pump assembly tolerances.
What manufacturing and intellectual-property barriers exist?
The main manufacturing barrier is reproducible production of a low-dose suspension with consistent spray delivery over the full container life.
Important control points include:
- Fluticasone particle-size distribution
- Azelastine hydrochloride particle characteristics
- Polymer dispersion and hydration
- Bulk suspension homogeneity
- Fill-volume control
- Pump metering accuracy
- Microbial limits
- Preservative effectiveness
- Container-closure integrity
- Actuator clogging
- In-use stability
A manufacturer that lacks nasal-spray filling and device-assembly capability may need a contract development and manufacturing organization. Capacity constraints can delay launch even after FDA approval.
Geographic coverage also affects economics. FDA approval supports the U.S. market only. European, Canadian, Japanese, and other national requirements may differ in reference-product standards, device assessment, excipient acceptability, and clinical or bioequivalence expectations. Global expansion requires jurisdiction-specific regulatory and patent analysis.
What are the best commercial opportunities?
The strongest opportunities are differentiated products that avoid direct commodity pricing.
Preservative-free unit-dose spray
A unit-dose product can eliminate or reduce the need for benzalkonium chloride. It may appeal to chronic users concerned about nasal irritation. The tradeoff is higher packaging cost, more material consumption, and less convenient portability.
Improved multidose device
A multidose system with better priming, reduced clogging, a reliable dose counter, and lower actuation force can improve patient adherence. Device differentiation is commercially attractive because it can be protected through engineering claims and human-factors data.
Lower-cost generic suspension
A conventional generic remains the largest-volume opportunity. Success depends on manufacturing scale, reliable active-ingredient supply, competitive contracting, and rapid approval. The product is vulnerable to price erosion once several manufacturers enter.
Pediatric and caregiver-focused presentation
The product is approved for children aged 6 years and older. A smaller actuator, clearer dose counter, and simpler priming process could support pediatric positioning, although any labeling or device claim must align with FDA requirements.[1]
Private-label and regional licensing
Retail, managed-care, and regional pharmaceutical companies may seek private-label supply. The opportunity is strongest in markets where combination nasal therapy has high seasonal demand and where a local manufacturer can secure reimbursement or pharmacy distribution.
How does azelastine/fluticasone compare with competing nasal products?
| Product type |
Strength |
Limitation |
| Azelastine/fluticasone combination |
Dual pharmacologic action in one spray |
More complex suspension and higher formulation burden |
| Fluticasone-only spray |
Established corticosteroid efficacy and broad availability |
Does not provide antihistamine activity |
| Azelastine-only spray |
Rapid antihistamine activity |
Less anti-inflammatory coverage |
| Oral antihistamine |
Convenient systemic administration |
May cause sedation or insufficient local control |
| Other combination nasal products |
Potential alternative dosing or device profiles |
Market access and comparative efficacy vary |
The fixed combination has a convenience advantage over sequential use of separate sprays. Its commercial weakness is that generic substitution can convert the product into a price-driven category unless the manufacturer differentiates the device or excipient system.
Key Takeaways
- Dymista is an FDA-approved fixed-dose nasal suspension containing azelastine hydrochloride and fluticasone propionate.
- The core excipient system uses microcrystalline cellulose, carboxymethylcellulose sodium, dextrose, benzalkonium chloride, polysorbate 80, disodium edetate, phenylethyl alcohol, and purified water.[1]
- Suspension stability, particle size, rheology, spray pattern, preservative control, and pump compatibility determine product quality.
- Regulatory exclusivity has expired; current commercial barriers are patents, device performance, manufacturing know-how, and market access.
- The product has no biosimilar risk because it is a small-molecule nasal spray.
- Generic entry is commercially credible and can produce rapid price erosion.
- The most attractive differentiated opportunities are preservative-free unit-dose products, improved multidose devices, and formulations with better tolerability or delivery consistency.
- Manufacturing capability is a material barrier because the product requires controlled suspension processing and validated nasal-pump performance.
FAQs
Is azelastine hydrochloride/fluticasone propionate a biologic drug?
No. It is a small-molecule combination product delivered as a nasal suspension. Biosimilar approval rules do not apply.
Can benzalkonium chloride be removed from the formulation?
Yes, but removal requires a redesigned microbial-control strategy, container system, stability program, and regulatory package. A preservative-free product may require unit-dose packaging.
Does a generic version need to use the same excipients as Dymista?
Not necessarily. A generic applicant generally must demonstrate that formulation differences do not affect safety, efficacy, quality, or performance. Nasal-spray device and suspension attributes remain critical.
Is fluticasone propionate soluble in the nasal spray?
No. Fluticasone propionate has very low aqueous solubility and is handled as a dispersed solid phase in the suspension.
What is the most defensible IP strategy for a new product?
The strongest strategy is likely to combine formulation claims with measurable particle, rheology, dose-uniformity, device, or manufacturing characteristics. Broad claims covering only the two active ingredients are less likely to provide durable exclusivity.
References
- U.S. Food and Drug Administration. (2023). Dymista: Azelastine hydrochloride and fluticasone propionate nasal spray prescribing information.
- National Library of Medicine. (2024). Dymista- azelastine hydrochloride and fluticasone propionate spray. DailyMed.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2015). Hatch-Waxman amendments and abbreviated new drug applications: Patent certification and litigation provisions.
